Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia.

Abstract

The thrombopoiesis-stimulating agents (TSAs) are a novel class of drugs for the treatment of chronic immune thrombocytopenia (ITP). Roimplostim and eltrombopag, the first two TSAs to enter clinical use, received regulatory approval in 2008 and stand poised to change the treatment paradigm in ITP. However, important questions regarding the safety of these… (More)

Topics

Cite this paper

@article{Cuker2010SafetyOT, title={Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia.}, author={Adam Cuker and Elaine Y. Chiang and Douglas B Cines}, journal={Current drug safety}, year={2010}, volume={5 2}, pages={171-81} }